The CAR-T cell therapy market is projected to grow at an annualized rate of 23%, claims Roots Analysis
The CAR-T cell therapy market is poised for significant growth, projected to reach a CAGR of 23% from 2022 to 2035. Over 970 therapies are currently approved or under development, with 25% in late-stage trials. The market's expansion is supported by substantial investments, totaling nearly USD 25 billion, primarily from US-based companies. Non-Hodgkin's lymphoma is expected to dominate the market, capturing 85% of target indications. The report highlights over 38,470 patients enrolled in around 750 clinical trials, indicating robust research and partnership activity.
- Projected market growth of 23% CAGR from 2022 to 2035.
- Over 970 CAR-T therapies approved or in development.
- Significant investment of nearly USD 25 billion in CAR-T therapies.
- Non-Hodgkin's lymphoma expected to capture 85% of the market share.
- None.
As the six approved CAR-T cell therapies, including Breyanzi®, Abecma™ and CARVYKTI™ are poised to achieve blockbuster status, the field of CAR-T cell therapies has gained significant traction
CAR-T cell therapies have been shown to enable complete disease remission, omitting the need for any further treatment. Several studies have proven the efficacy of these therapy candidates. Driven by the ongoing pace of innovation and sufficient financial support from investors, the CAR-T cell therapy market is anticipated to witness substantial growth in the foreseen future
To order this 650+ page report, which features 350+ figures and 190+ tables, please visit https://www.rootsanalysis.com/reports/view_document/car-t-therapies-market/269.html
Key Market Insights
Over 970 CAR-T cell therapies are currently approved / under development
Over
Extensive efforts are underway to improve CAR constructs
Majority of the CAR-T cell therapies in clinical development, along with the six recently approved products, are based on second generation CARs. Further, lentivirus and retrovirus are presently the preferred type of vectors used for transduction of CAR constructs into T-cells.
More than 38,470 patients have been enrolled in around 750 clinical trials, worldwide
Clinical research activity, in terms of number of trials registered, is reported to have increased over the last five years. Of the total number of trials, more than
Partnership activity within this domain has grown at a CAGR of
Over 280 agreements have been inked in the last 5 years. Majority of partnership deals signed within this domain were licensing agreements (
Amount close to
Specifically, in 2020 and 2021, industry players raised over
More than 6,500 patents have been filed / published related to the CAR-T cell therapies
Close to
The market is anticipated to grow at a CAGR of
Currently, non-Hodgkin's lymphoma (
To request a sample copy / brochure of this report, please visit
https://www.rootsanalysis.com/reports/view_document/car-t-therapies-market/269.html
Key Questions Answered
- What are the prevalent R&D trends related to CAR-T cell therapies?
- What are the different types of clinical conditions that can be treated using CAR-T cell therapies?
- Who are the leading industry and non-industry players in this market?
- In which geographies, extensive research on CAR-T cell therapy is being conducted?
- What kind of partnership models are commonly adopted by industry stakeholders?
- Who are the key investors in the CAR-T cell immunotherapy domain?
- Who are the key opinion leaders / experts from renowned academic and research institutes proficient to help drive product development efforts in this domain?
- How is the intellectual property landscape for global CAR-T cell therapies likely to evolve in the foreseen future?
- Who are the key service providers (CMOs / CDMOs) with capabilities to develop and manufacture CAR-T cell therapies?
- What are the key factors that are likely to influence the evolution of the CAR-T cell immunotherapies market?
- How is the current and future market opportunity likely to be distributed across key market segments?
- What are the key promotional strategies used by companies having marketed products?
The financial opportunity within the CAR-T cell therapies market has been analyzed across the following segments:
- Target Indication(s)
- Non-Hodgkin's Lymphoma
- Multiple Myeloma
- Acute Lymphoblastic Leukemia
- Chronic Lymphocytic Leukemia
- Hodgkin's Lymphoma
- Acute Myeloid Leukemia
- Ovarian Cancer
- Generalized Myasthenia Gravis (MG)
- Renal Cell Carcinoma
- Target Antigen
- CD19
- BCMA
- CD19/22
- Others
- Key Geographical Regions
North America Europe Asia Pacific Latin America Middle East andNorth Africa - Rest of the World
The report features inputs from eminent industry stakeholders, according to whom, T-cell immunotherapies are expected to be the next big step in cancer immunotherapy. The report includes detailed transcripts of discussions held with the following experts:
- Troels Jordansen (Chief Executive Officer, Glycostem Therapeutics)
Wei (William) Cao (Chief Executive Officer,Gracell Biotechnologies )Miguel Forte (Chief Operating Officer, TxCell)Adrian Bot (Vice President, Scientific Affairs, Kite Pharma)Vincent Brichard (Vice President, Immuno-Oncology, Celyad)Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing)Aino Kalervo (Former Competitive Intelligence Manager, Strategy & Business Development,Theravectys )Xian-Bao Zhan (Professor of Medicine and Director,Department of Oncology ,Changhai Hospital )Enkhtsetseg Purev (Assistant Professor of Medicine,University of Colorado )
The report includes brief profiles of key players (listed below); each profile features an overview of the company, details related to its financial information (if available), details about CAR-T-cell based product(s), such as information on type of therapy and current development status, information on technology portfolio (if available), recent developments related to CAR-T cell immunotherapies and manufacturing capabilities of the players.
Autolus - bluebird Bio
- Bristol Myers Squibb
Carsgen Therapeutics - Cellectis
- Cellular Biomedicine Group
- Gilead Sciences
- Innovative Cellular Therapeutics
- Kuur Therapeutics
- Noile-Immune Biotech
- Novartis
- Shanghai GeneChem
- Sinobioway Cell Therapy
- Takara Bio
- Wellington Zhaotai Therapies
For additional details, please visit https://www.rootsanalysis.com/reports/view_document/car-t-therapies-market/269.html or email sales@rootsanalysis.com
You may also be interested in the following titles:
- Global T-Cell (CAR-T, TCR, and TIL) Therapy Market (6th Edition), 2022- 2035
- Antiviral Drugs Market, 2022-2035
- mRNA Therapeutics and mRNA Vaccines Market (2nd Edition), 2022-2035
https://www.rootsanalysis.com/reports/aseptic-filling-systems-market.html
Contact:
+1 (415) 800 3415
+44 (122) 391 1091
Gaurav.Chaudhary@rootsanalysis.com
Logo: https://mma.prnewswire.com/media/742223/Roots_Analysis_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/the-car-t-cell-therapy-market-is-projected-to-grow-at-an-annualized-rate-of-23-claims-roots-analysis-301742759.html
SOURCE Roots Analysis
FAQ
What is the projected growth rate of the CAR-T cell therapy market?
How many CAR-T cell therapies are currently in development?
What amount has been invested in CAR-T cell therapies?
What percentage of the CAR-T market is expected to be made up of Non-Hodgkin's lymphoma?